Clozapine vs Quetiapine (Seroquel)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)
Result source: NCT03510325
Quetiapine (Seroquel)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00305422 · Phase 3 · completed
The study was randomized and double-blinded with an active risperidone comparator, but its small sample of 45 participants limits the strength of the evidence. The primary comparison was not reported, and the primary focus included cognitive and functional brain-activation measures rather than a clearly specified hard clinical endpoint.
Next expected readout: February 2032 · NCT07152184 (registry estimate)
Reported efficacy
Clinical efficacy of both neuroleptics, especially with regard to cognitive deficits and functional brain activation between baseline and week 12: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).
Result source: NCT00305422
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Clozapine | Quetiapine (Seroquel) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00649844 | -24 vs -15.9−8.1 vs placeboNCT018103801 other result
|
| CGI-S, change | —Not posted · NCT00649844 | -1.4 vs -0.9−0.5 vs placeboNCT018103801 other result
|
| PANSS response | —Not posted · NCT00649844 | 62.7% vs 32.1%+30.6 vs placeboNCT01810380 |
| PSP, change | —Not posted · NCT00649844 | 15.3 vs 9.4+5.9 vs placeboNCT01810380 |
| Relapse (% of patients) | —Not posted · NCT00649844 | —Not posted · NCT00305422 |
PANSS total, change
- Clozapine
- —Not posted · NCT00649844
- Quetiapine (Seroquel)
- -24 vs -15.9−8.1 vs placeboNCT01810380
1 other result
- -33.4 vs -35.9 NCT00882518
CGI-S, change
- Clozapine
- —Not posted · NCT00649844
- Quetiapine (Seroquel)
- -1.4 vs -0.9−0.5 vs placeboNCT01810380
1 other result
- -1.8 vs -2.1 NCT00882518
PANSS response
- Clozapine
- —Not posted · NCT00649844
- Quetiapine (Seroquel)
- 62.7% vs 32.1%+30.6 vs placeboNCT01810380
PSP, change
- Clozapine
- —Not posted · NCT00649844
- Quetiapine (Seroquel)
- 15.3 vs 9.4+5.9 vs placeboNCT01810380
Relapse (% of patients)
- Clozapine
- —Not posted · NCT00649844
- Quetiapine (Seroquel)
- —Not posted · NCT00305422
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Clozapine: 3 of 4 rows · Quetiapine (Seroquel): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Clozapine | Quetiapine (Seroquel) |
|---|---|---|
| Dropout rate | 41.7%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT00498550 · Phase 4 · registry result, not featured evidence 17.2% NCT02404155 · Phase na · registry result, not featured evidence | —Seroquel IRa NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results—Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 30.4% NCT00156715 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 20.8%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 19.4% NCT00882518 · Phase 3 · registry result, not featured evidence 37.8% NCT00227305 · Phase 3 · registry result, not featured evidence 16.7% NCT00642369 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results— NCT00498550 · Phase 4 · registry result, not featured evidence — NCT02404155 · Phase na · registry result, not featured evidence | —Seroquel IRa NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results—Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence — NCT00156715 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 2.6%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 4.6% NCT00882518 · Phase 3 · registry result, not featured evidence 10.5% NCT00227305 · Phase 3 · registry result, not featured evidence 6.7% NCT00642369 · Phase na · registry result, not featured evidence |
| Serious AEs | 13%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results26.7% NCT00498550 · Phase 4 · registry result, not featured evidence 6.9% NCT02404155 · Phase na · registry result, not featured evidence | 0%Seroquel IRa NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results0%Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 18.8% NCT00156715 · Phase 4 · registry result, not featured evidence 1.3%Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence —Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 0% NCT00882518 · Phase 3 · registry result, not featured evidence 12.1% NCT00227305 · Phase 3 · registry result, not featured evidence 0% NCT00642369 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a other-sialorrhea 43.5% weight gain 30.4% sedation 21.7% NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more resultsgastrointestinal disorder - other: hypersalivation 66.7% somnolence 60% weight gain 40% NCT00498550 · Phase 4 · registry result, not featured evidence salivation 68.2% sedation 52.9% malaise 52.6% NCT02404155 · Phase na · registry result, not featured evidence | a somnolence 3.2% delusion 1.6% dizziness 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence show 5 more resultspsychotic disorder 1.6% sedation 1.6% sleep disorder 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence dry mouth 43.8% sedation 43.8% increased appetite/weight gain 31.3% NCT00156715 · Phase 4 · registry result, not featured evidence somnolence 22.2% (placebo 5%) weight increased 13.1% (placebo 3.7%) dizziness 11.8% (placebo 0.6%) NCT01810380 · Phase 3 · registry result, not featured evidence constipation 25% dizziness 14.3% insomnia 12.8% NCT00882518 · Phase 3 · registry result, not featured evidence somnolence 30.3% increased appetite 20% sedation 18.9% NCT00227305 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Clozapine
Quetiapine (Seroquel)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 12 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Quetiapine (Seroquel)'s landscape